- Home
- TDC vs IMCR Comparison
TDC vs IMCR Comparison
Compare TDC & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDC
- IMCR
- Stock Information
- Founded
- TDC 1979
- IMCR 2008
- Country
- TDC United States
- IMCR United Kingdom
- Employees
- TDC N/A
- IMCR N/A
- Industry
- TDC Computer Software: Prepackaged Software
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TDC Technology
- IMCR Health Care
- Exchange
- TDC Nasdaq
- IMCR Nasdaq
- Market Cap
- TDC 1.9B
- IMCR 1.7B
- IPO Year
- TDC 2007
- IMCR 2021
- Fundamental
- Price
- TDC $27.66
- IMCR $32.21
- Analyst Decision
- TDC Hold
- IMCR Buy
- Analyst Count
- TDC 7
- IMCR 9
- Target Price
- TDC $27.33
- IMCR $66.88
- AVG Volume (30 Days)
- TDC 1.6M
- IMCR 300.4K
- Earning Date
- TDC 11-04-2025
- IMCR 11-06-2025
- Dividend Yield
- TDC N/A
- IMCR N/A
- EPS Growth
- TDC 44.28
- IMCR N/A
- EPS
- TDC 1.21
- IMCR N/A
- Revenue
- TDC $1,651,000,000.00
- IMCR $379,590,000.00
- Revenue This Year
- TDC N/A
- IMCR $30.11
- Revenue Next Year
- TDC N/A
- IMCR $8.89
- P/E Ratio
- TDC $23.40
- IMCR N/A
- Revenue Growth
- TDC N/A
- IMCR 28.11
- 52 Week Low
- TDC $18.43
- IMCR $23.15
- 52 Week High
- TDC $33.20
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- TDC 72.53
- IMCR 46.53
- Support Level
- TDC $20.54
- IMCR $30.50
- Resistance Level
- TDC $28.62
- IMCR $34.50
- Average True Range (ATR)
- TDC 0.82
- IMCR 1.46
- MACD
- TDC 0.79
- IMCR -0.11
- Stochastic Oscillator
- TDC 86.51
- IMCR 42.63
About TDC Teradata Corporation
Teradata Corp focused on helping organizations improve business performance, enrich customer experiences, and integrate data across the enterprise. The company's platform provides companies with Harmonized Data: Trusted AI: Teradata VantageCloud: Teradata VantageCore: ClearScape Analytics: and Query Grid. The company generates majority of revenue from the United States.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.